RxDoctor Payments Data

Aaron Vanwagnen, MD

Internal Medicine · Jackson, MINPI 1245305044

Payments from drug & device makers

$2,383in general payments, 2019–2025

Across 157 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$547
  • Pfizer$327
  • Amgen$264
  • Novartis$194
  • Lilly USA, LLC$180
  • AbbVie$164
  • plus $706 from 16 others

What the payments were for

  • Food & beverage$2,383100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,383 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$74,454
Medicare patients
97
Services billed
905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban40$64,971
EliquisApixaban47$58,283
OzempicSemaglutide31$57,505
JardianceEmpagliflozin48$51,685
Bydureon BciseExenatide Microspheres24$27,296
Repatha SyringeEvolocumab36$19,318
MounjaroTirzepatide11$18,629
Lantus SolostarInsulin Glargine,hum.Rec.Anlog79$15,000
Epinephrine40$10,518
Pitavastatin Calcium44$10,049
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl15$8,790
EntrestoSacubitril/Valsartan12$7,927
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,866
Repatha SureclickEvolocumab12$6,526
Rosuvastatin Calcium283$5,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$137$64,97140 claims
PfizerEliquis, Premarin$327$61,21661 claims
Novo NordiskOzempic$547$57,50531 claims
Lilly USA, LLCMounjaro$180$18,62911 claims
NovartisEntresto$194$7,92712 claims
GSKTrelegy Ellipta$18$6,86611 claims
Sanofi-aventis U.S. LLCLantus$32$5,07139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Jackson

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →